Crinetics Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc.

Sun Hee Kim

Sangdon Han

Yunfei Zhu

Jian Zhao

Shimiao Wang

Robert M Jones

Juerg Lehmann

Daniel J Buzard

Xiuwen Zhu

Brett Ullman

Jeanne V Moody

Andrew Mamoru Kawasaki

Lars Thoresen

Scott Stirn

Weichao George Chen

Abu J M Sadeque

Jeffrey Edwards

Michael E Morgan

Scott Stim

Glen Marquez

Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Somatostatin modulators and uses thereof

The present invention relates to the GPR119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-imethylbenzamide; 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide; and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPRI19-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

Modulators of the GPR119 receptor and the treatment of disorders related thereto

Growing community of inventors

San Diego, CA, United States of America

Sun Hee Kim